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and future trials should compare to real-world treatments wherever possible to
demonstrate clinically-meaningful differences.
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OBJECTIVES: Enhancements in renal transplant have led to reduced rates of acute
rejection leading to a shift to kidney function as an accepted endpoint in efficacy
trials. Characterizing long-term benefits requires modeling to project long-term
outcomes of treatment based on kidney function. The goal of this study was to
project rates of graft failure and quality adjusted life years over the lifetimes of
hypothetical patients receiving belatacept (a recently-introduced selective co-
stimulation blocker), cyclosporine or tacrolimus. METHODS: We developed a sim-
ulation with two phases that integrated trial-based information with a long-term
four-state Markov model (functioning graft, graft failure on dialysis, functioning
re-graft, and death). In the first phase, three-year distributions of patients in four
estimated glomerular filtration rate (eGFR) categories (60, 45-59, 30-44 and 15-29,
with graft failure assumed at eGFR 15 mLs/min/1.73m2) were estimated using a
mixed treatment comparison of cyclosporine, belatacept, and tacrolimus. The
Markov phase was populated using transplant recipient data from the United
States Renal Data System (n34,130). Utilities for adjusting life-years were ob-
tained from a study of US renal transplant patients. RESULTS: Over a 20-year
modeled time-horizon for 1,000 hypothetical patients, belatacept was associated
with 551 graft failures,and 9.6 quality-adjusted life years. Relative to cyclosporine,
belatacept was associated with 0.9 additional quality-adjusted life years, and 56
fewer graft failures. Relative to tacrolimus, belatacept was associated with 0.9 ad-
ditional quality-adjusted life years, and 18 fewer graft failures. CONCLUSIONS:
This is the first long-term follow-up model of renal transplant patients to be based
on trial-based graft function endpoints and include all relevant comparators. This
long-term extrapolation of differences in kidney function observed at three years
shows clinically important differences between treatments. While validation of
these models will require long-term follow-up of patients, modeling based on renal
function may prove to be a useful method of projecting long-term outcomes.
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BACKGROUND: Belatacept is a first in-class co-stimulation blocker developed for
primary maintenance immunosuppression following renal transplantation. Data
is widely available comparing belatacept to cyclosporine, limited data is available
comparing it with other immunosuppressants. OBJECTIVES: Estimate belatacept’s
efficacy and safety relative to tacrolimus. METHODS: A systematic review was
conducted of randomised controlled trials (RCTs) published between January 1990
and September 2010. Data extraction captured study duration, quality, baseline
data, treatment and clinical outcomes. Efficacy and safety outcomes included glo-
merular filtration rate (GFR), graft- and patient-survival, and acute rejection (AR).
The data were analysed with fixed- and random-effects models. Linear models
with outcome of mean difference were applied for GFR because GFR (ml/min) is a
continuous measure, unlike the other variables which are dichotomous in nature.
Logistic models were used for these other outcomes (summary measure being odds
ratios). Sensitivity analyses (SAs) were conducted based on trial durations and
sub-populations.RESULTS:We identified twenty-six RCTs comparing cyclosporine
with tacrolimus, three RCTs comparing cyclosporine with belatacept, and no trials
comparing tacrolimus with belatacept. Most trials were 12 months in duration
(range: 6 to 60 months). MTC results using 36 month belatacept data suggested
benefits with belatacept on patient survival (OR0.62 95%CI: 0.31,1.24), and differ-
ence in GFR (8.50 ml/min/1.73 m2; 95% CI ( 4.22,20.44), versus tacrolimus, with AR
outcomes favouring tacrolimus (OR2.43; 95%CI 1.08,5.34). MTC results indicated
reduced graft-survival with belatacept at 36 months (OR1.18 95%CI: 0.51,2.85).
However, SAs using data at 12 months post-transplant demonstrated a benefit for
belatacept on graft-survival (OR0.89 95%CI: 0.36,2.16). Benefits on graft-survival
were also seen at 12 and 24 months in the standard-criteria donor population. SAs
on the other outcomes resulted in similar conclusions to those of the base case.
CONCLUSIONS: Belatacept showed improved renal function and benefits in graft-
and patient-survival in comparison to tacrolimus despite increased risks for AR.
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OBJECTIVES: Assess the impact of the treatment of urinary disorders of the lower
urinary tract related to benign prostatic hypertrophy (BPH) using medical treat-
ment under actual conditions of use. METHODS: A pragmatic cohort of patients
treated medically, was followed up for 6 months, using validated questionnaires:
IPSS and MSF4. RESULTS: Fifty-one patients treated with Serenoa Repens (hexanic
extract) were evaluated, the mean age was 61.51 8.11 years, and on average the
diagnosis had been made 3.6 months previously.At 6 weeks, the IPSS was signifi-
cantly improved (p0.0001). This improvement in the IPSS score between 6 weeks
(10.155.36) and inclusion (13.766.03) was 3.6 points. An improvement was also
observed at 3 months. At 6 months, the p-value was also significant (p0.0001). The
improvement in the IPSS score between 6 months (6.903.46) and inclusion
(12.936.09) was 6 points.The MSF4 was unchanged. CONCLUSIONS: We observed
an improvement in the IPSS score from the sixth week; this statistical improve-
ment was confirmed by a significant clinical improvement in the sixth month.
Urinary/Kidney Disorders – Cost Studies
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OBJECTIVES: To analyze the cost savings after the consecutive introduction of the
generic immunospressants Azathioprine, Mycophenolic acid and Ciclosporin for
patients with transplanted kidney in Bulgaria. METHODS: Prospective observa-
tional study of the pharmacotherapy cost of patients after kidney transplantation
during 36 months (Mar 2008 – February 2011) was performed; 528 patients switched
to at least one of the generic immunosupressors were followed. Patients were
classified in 3 periods – beginning, during and after the switch. It was also followed
the changes in the whole pharmacotherapy as an indicator for switch compliance.
Mean cost per patient and cost saving were calculated. RESULTS: A total of 433
patients were treated with combined immunosuppressive therapy containing at
least one of the 4 originators (Imuran, Myfortic, Cellcept, Sandimmune) through
the Period 1 and then consecutively they increase to 528. Per patient cost of therapy
with the observed medications differs among the age groups and among the peri-
ods with low cost for age group of up to 70 years old. The introduction of generic
Azathioprine in 2009 reduced the mean pharmacotherapy cost for all patients with
6% from 4814 - 4539 BGN (2461 - 2321EUR). At the same time the introduction of
generic mycophenolic acid‘s derivates and appearance of generic ciclosporin in
2010 reduced the mean pharmacotherapy cost of the observed patients more than
2 times (119%) from 4539 – 2076 BGN (2321 – 1061 EUR). Total reduction of the mean
pharmacotherapy cost (Period 1 vs. Period 3) was 132% from 4814 – 2076 BGN (2461
– 1061 EUR). No other changes in the pharmacotherapy were observed, as well as no
back transfer to originator products. CONCLUSIONS: The introduction of generic
immunosuppressors significantly decreased the mean cost of therapy and let to
high cost savings for the hospital budget without any additional changes in the
patients’ pharmacotherapy.
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OBJECTIVES: To elucidate patient and economic burden associated with chronic
kidney disease (CKD) across countries. METHODS: A targeted literature review
using PubMed and desktop research was performed. Currency conversions were
adjusted to 2010. RESULTS: North American, European, and Asian studies were
identified; most reports were from the United States (US). Advanced CKD (stages
3-5) adversely affects outcomes. As patient-reported outcomes (PROs) deteriorate,
resource utilization (RU) and costs escalate. Across studies, patients with CKD
report cognitive impairment, dementia, sleep disturbance, and emotional and
physical dysfunction (PD), with PD being most pervasive. Compared with general
populations across countries, Health-related Quality of Life (HRQOL) and other
PROs decline in patients with CKD. Age, female gender, less education, lower in-
come, unemployment, limited exercise, and comorbid illness are predictors of re-
duced HRQOL. RU and costs to healthcare systems and employers increase with
CKD severity. Prior to (12-24 months) dialysis initiation, costs increase substan-
tially due to hospitalization. Annual US total cost per patient (c/p/p) with CKD
(stages 3-5) range from $6,026 (€4,927) to $30,398 (€24,855); annual Germany total
c/p/p (stages 1-4) is €3,581 ($4,379), compared to €1,272 ($1,555) in those without
CKD. The cost burden of CKD is rising. From 1993 to 2007, Medicare costs for pa-
tients with CKD increased by 5-fold. High healthcare costs (HC) and reduced
productivity due to CKD, burdens employers. For employees with CKD (US), HCs
range from $1,187 (€971) (stage 3) to $21,826 (€17,846) (stage 5) and work-hours
missed per week often exceeds 10. The impact of CKD on patient and economic
burden across countries is evident. CONCLUSIONS: Patient and economic burden
associated with CKD is considerable across countries. With disease progression
and kidney-function decline, unfavorable outcomes arise. As evidenced by the high
patient and economic burden of CKD, a large unmet need exists for new therapies
and employee CKD-management programs.
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OBJECTIVES: Evaluate if the use of Methoxy polyethylene-glycol erythropoietin
beta (MPG-beta) offers better health outcomes and costs with respect to erythro-
poietin beta multidose presentation (50,000 IU). METHODS: Analysis of incremen-
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tal cost-effectiveness based on a decision tree to simulate the costs of treatment,
with a time horizon of 12 months (nominal cost).The monthly dose of erythropoi-
esis stimulating agents was adjusted according to hemoglobin levels, if the con-
centration is greater than 12.5 g/dl 10.000 IU/month of erythropoietin beta or 0.6
mcg/kg/month of MPG-beta, for 11 -12.5 g/dl 20.000 IU/month of erythropoietin
beta or 1.2 mcg/kg/month of MPG-beta and concentrations below 11 g/dl 40.000
IU/month of erythropoietin beta or 1.5 mcg/kg/month of MPG-beta. Each scenario
has a cost based on usual care of these patients. The direct costs were taken from
the current rates for 2010 apply to medical services provided by IMSS. We deter-
mined the risk of not being in an ideal range of hemoglobin (11-12.5 g/dl), also
known as hemoglobin excursions and associated costs. RESULTS:MPG-beta main-
tains a more stable hemoglobin concentration when compared with erythropoietin
beta, so that at 6 months of treatment remain in the ideal range 94% versus 80%
with erythropoietin beta. With the use of erythropoietin beta there is a greater risk
of having excursions. The incremental cost-effectiveness analysis shows a 13%
increase in effectiveness for only an additional $30 USD annually using MPG-beta
compared with erythropoietin beta, this derived from the stability of hemoglobin.
The ICER is $2.3 USD per incremental percentage of effectiveness. CONCLUSIONS:
These results demonstrate that MPG-beta offers better health outcomes against an
almost insignificant cost increase being as a cost effective treatment.
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OBJECTIVES: To carry out a cost-utility analysis comparing initial treatment with
solifenacin 5 mg/day versus oxybutynin immediate-release (IR) 15 mg/day for the
treatment of patients with overactive bladder (OAB) from the perspective of the UK
National Health Service (NHS). METHODS: A Markov model with six health states
was developed in EXCEL to follow a cohort of OAB patients treated with either
solifenacin or oxybutynin during a one year period. Costs and utilities were accu-
mulated as patients transited through the health states in the model including a
drop-out state. Some of the solifenacin patients were titrated from 5mg to 10mg/
day at 8 weeks. A proportion of drop-out patients were assumed to continue treat-
ment with tolterodine ER. Utility values were obtained from a Swedish study and
pad use was based on a multinational clinical trial. Adherence rates for individual
treatments were derived from a UK database study. For pad use and utility values,
the drop-out state was split between those patients who were no longer receiving
treatment and those on second-line therapy. Patients on second-line therapy who
drop-out were referred for a specialist visit. Results were expressed in terms of
incremental cost-utility ratios. RESULTS: Total annual costs for solifenacin and
oxybutynin were £504.30 and £414.10 respectively. First-line drug use represents
49% and 16% of costs and pad use represent 23% and 35% of costs for solifenacin
and oxybutynin respectively. Differences between cumulative utilities were small
but were greater for solifenacin (0.7020 vs. 0.6907). The baseline incremental cost-
effectiveness ratio was £7,921/QALY. CONCLUSIONS: Under our baseline assump-
tions, solifenacin is cost-effective with an incremental cost-utility of less than
£20,000/QALY. However, small differences in utility between the alternatives and
the large number of drop-outs means that the results are sensitive to small adjust-
ments in the values of utilities assigned to the drop-out state.
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OBJECTIVES: To compare 1-year treatment cost of initial continuous renal replace-
ment therapy (CRRT) vs. intermittent daily hemodialysis (IHD) or slow extended
daily dialysis (SLEDD) in critically ill patients with acute renal failure in Germany.
METHODS: As differences in hospital survival rates among the evaluated renal
replacement therapies (RRT) are not evident, a cost-minimization model was de-
veloped to compute potential direct medical costs associated with dialysis for each
treatment group. The preliminary analysis has been performed from the perspec-
tive of the German statutory health insurance. Model input data was derived from
published literature and complemented by expert opinion in case of missing
information. RESULTS: Total estimated average per-patient hospital costs were
found to be similar for the evaluated hypothetical RRT cohorts, amounting to
€12,380 for CCRT, €12,650 for IHD, and €12,528 for SLEDD. Whereas costs of dispos-
ables are substantially higher for CRRT than for IHD/SLEDD, these incremental
costs were largely offset by an expected average ICU stay reduction of one day
owing to assumed minor treatment benefits for CRRT. As sufficiently powered,
randomized comparative trials are currently lacking, we assumed equivalent hos-
pital mortality for each analyzed RRT treatment group as shown in meta-analyses,
but a slightly higher renal recovery rate at discharge for CRRT than for IHD/SLEDD
(87.8% vs. 80.0%) as indicated by several studies. Consequently, follow-up costs
involving chronic RRT in survivors remaining dialysis dependent after discharge
were lower for CRRT than for IHD/SLEDD resulting in total first year average per-
patient costs of €14,020 vs. €16,527/€16,374, respectively. Findings from multivari-
ate sensitivity analyses support the robustness of these preliminary outcomes.
CONCLUSIONS: In the absence of published data, our exploratory economic anal-
ysis provides first indications of potentially lower total first-year costs for initial
CRRT than for IHD/SLEDD. To corroborate these findings, supplementary and con-
sistent clinical and resource use data is warranted.
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OBJECTIVES: Chronic kidney disease (CKD) afflicts up to 26 million people in the
US, but limited information exists about the associated health care costs, especially
in earlier stages of CKD patients with diabetes mellitus (DM). The objective of this
study was to evaluate the medical resource use in US patients diagnosed with CKD
with and without DM. METHODS: A large administrative claims database (Market-
Scan) was used to conduct this retrospective study. Patients aged 18 diagnosed
for CKD between January 1, 2007 to December 31, 2008 with 12 months of contin-
uous pharmaceutical and medical benefit coverage were identified. CKD patients
with DM were defined as receiving a diagnosis code for DM or1 prescription filled
for an antidiabetic medication during the 12-month follow-up period. Multivariate
analysis was conducted controlling for baseline differences between CKD w/DM
and CKD w/o DM cohorts.RESULTS:There were 116,512 patients that met inclusion
criteria with mean age of 65 years and 56% male. Forty-five percent of CKD patients
had a diagnosis for DM during the follow-up period. CKD w/DM had more CKD
related and non-CKD related medical visits in 12 months than CKD w/o DM (12 vs.
9 mean visits, 38 vs. 25 mean visits; all p0.0001). Additionally, adjusted CKD
related medical costs for CKD w/DM were $11,431 annually (p0.0001), compared
to $8,975 for CKD w/o DM. Mean pharmacy costs for CKD w/ DM were also signifi-
cantly higher than CKD w/o DM ($7,206 vs. $5,941, p0.0001). Thus, total mean
adjusted costs (medical & drug) for CKD w/DM were 9% higher than CKD w/o DM
($38,262 vs. $34,759, p0.0001). CONCLUSIONS: In this retrospective study, the
annual medical visits and total healthcare costs were significantly higher for CKD
patients with diabetes compared to CKD patients without comorbid diabetes. This
was particularly evident in the very early and late stages of CKD.
Urinary/Kidney Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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OBJECTIVES: Evaluates if modifying the epidemiology of renal disease, more pa-
tients in predialysis and less in dialysis, improves the quality of life Chronic Kidney
Disease (CKD) is a long-term condition described as the gradual loss of kidney
function over time There are various stages of chronic renal failure prior to dialysis
which are also considered as kidney failure. Those in stages III and IV present a
significant percentage of complications from CKD which damage the renal func-
tion and accelerate the need of dialysis. Medical literature suggests early treatment
of renal anemia, proteinuria and hypertension in patients who have not reached
the renal replacement therapy Preventing complications, through adequate care of
known progression factors (diabetes, hypertension, correction of anemia, and pro-
teinuria), of CKD in predialysis stages reduces the progression of renal disease.
Progression of renal damage can be slow down through early intervention preven-
tive treatments such as control of glucose levels, anemia, hypertension and pro-
teinuria in the early stages of the disease.METHODS:We developed a simulation of
1000 patients from predialysis stage coming to dialysis in a period of 30 months.
RESULTS: Without prevention treatment 57% of the patients will require dialysis,
1% will be transplanted and 9.1% will die, while with the prevention treatment only
25% will require dialysis, 0.5% will be transplanted and 4% will die during this
period. CONCLUSIONS: The early treatment of patients provides better quality of
life and significant savings compared with dialysis. Transplantation as a form of
replacement therapy is the best choice for quality life and cost.
Urinary/Kidney Disorders – Health Care Use & Policy Studies
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OBJECTIVES: To understand the trends in rate and cost of hospitalizations due to
Chronic Kidney Disease (CKD) in the United States. METHODS: We analyzed last
five years of hospitalizations with ICD-9 diagnosis codes of CKD and End Stage
Renal Disease (ESRD). The annual number of hospitalizations for specific diagnosis
were obtained from AHRQ’s National In-patient Sample (NIS) databases of 2005-
2009. Data were also analyzed for length of stay (LOS), charges and cost of
hospitalization. RESULTS: During last five years the number of hospitalizations
with diagnosis of CKD and ESRD have increased 4.1 and 4.6 fold, respectively. In
2009, an estimated 1,634,422 and 931,641 hospitalizations were with diagnosis of
CKD and ESRD, respectively. The mean LOS for patients with CKD has increased
from 4.9 to 5.5 days, during 2005-2009. The mean LOS for patients with ESRD has
remained steady at 6 days during 2005-2009. The cost of hospitalization with
diagnosis of CKD has increased 31% during 2005-2009. The cost of hospitalization
with diagnosis of ESRD has increased 21% during 2005-2009. In 2009, the mean cost
of hospitalization for patients with CKD and ESRD were $11,209 and $21,358,
respectively. CONCLUSIONS: Hospitalizations due to CKD and ESRD have signifi-
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